The Pennant Group, Inc. (NASDAQ:PNTG) Receives Average Rating of “Buy” from Analysts

The Pennant Group, Inc. (NASDAQ:PNTG) has earned a consensus recommendation of “Buy” from the eight analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $34.80.

A number of equities research analysts have recently commented on the stock. Jefferies Financial Group initiated coverage on shares of The Pennant Group in a report on Friday, October 24th. They set a “buy” rating and a $30.00 price target on the stock. Zacks Research upgraded The Pennant Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 20th. William Blair started coverage on The Pennant Group in a research report on Monday. They issued an “outperform” rating for the company. Wall Street Zen upgraded shares of The Pennant Group from a “hold” rating to a “buy” rating in a research note on Monday, November 24th. Finally, Stephens reissued an “overweight” rating and set a $40.00 price objective on shares of The Pennant Group in a report on Thursday, October 9th.

The Pennant Group Trading Up 1.5%

NASDAQ:PNTG opened at $29.51 on Friday. The firm has a market capitalization of $1.02 billion, a P/E ratio of 39.35, a P/E/G ratio of 2.34 and a beta of 1.31. The company has a fifty day moving average of $25.98 and a 200 day moving average of $25.78. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.08. The Pennant Group has a 52 week low of $21.18 and a 52 week high of $30.43.

The Pennant Group (NASDAQ:PNTG) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.01. The business had revenue of $229.04 million for the quarter, compared to analysts’ expectations of $221.96 million. The Pennant Group had a return on equity of 9.37% and a net margin of 3.15%.The Pennant Group has set its FY 2025 guidance at 1.140-1.180 EPS. On average, research analysts predict that The Pennant Group will post 0.75 earnings per share for the current year.

Hedge Funds Weigh In On The Pennant Group

A number of institutional investors have recently bought and sold shares of PNTG. Invesco Ltd. grew its stake in The Pennant Group by 9.9% during the first quarter. Invesco Ltd. now owns 48,945 shares of the company’s stock valued at $1,231,000 after acquiring an additional 4,425 shares in the last quarter. Nuveen LLC purchased a new position in shares of The Pennant Group during the first quarter valued at about $9,181,000. American Century Companies Inc. bought a new stake in shares of The Pennant Group in the first quarter worth about $519,000. Algert Global LLC increased its holdings in shares of The Pennant Group by 39.9% in the first quarter. Algert Global LLC now owns 136,441 shares of the company’s stock worth $3,431,000 after purchasing an additional 38,890 shares during the last quarter. Finally, Versor Investments LP lifted its position in shares of The Pennant Group by 6.2% in the first quarter. Versor Investments LP now owns 12,000 shares of the company’s stock worth $302,000 after buying an additional 700 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

The Pennant Group Company Profile

The Pennant Group, Inc provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families.